Please sign in so that we can notify you about a reply
Indications/Uses
Vascular pathologies with thrombotic risk, transient ischemic attacks and cerebrovascular disease, peripheral vascular insufficiency, diabetic retinopathy, myocardial infarction, retinal vasal thrombosis.
Dosage/Direction for Use
It is generally suggested that ampules be used to start treatment and that after 15-20 days be continued with capsules for 30-40 days. The complete treatment cycle must be repeated at least twice yearly. Depending on the physician's evaluation, the quantity and frequency of the dosage may vary.
Capsule: 1-2 capsules twice daily, 30 min before meals.
Injection: 2 mL IM or IV daily.
Capsule: 1-2 capsules twice daily, 30 min before meals.
Injection: 2 mL IM or IV daily.
Administration
Should be taken on an empty stomach: Take 30 min before meals.
Contraindications
Individual hypersensitivity towards Vessel Due-F, towards heparin and heparin-like products.
Diathesis and hemorrhagic diseases.
Diathesis and hemorrhagic diseases.
Special Precautions
In all cases where anticoagulant treatment is under way, hemocoagulative parameters should be monitored periodically.
Use in pregnancy: Due to precautionary reasons, the administration of Vessel Due-F to pregnant women is not recommended.
Use in pregnancy: Due to precautionary reasons, the administration of Vessel Due-F to pregnant women is not recommended.
Use In Pregnancy & Lactation
Use in pregnancy: Due to precautionary reasons, the administration of Vessel Due-F to pregnant women is not recommended.
Adverse Reactions
Cap: Occasionally GI disorders eg, nausea, vomiting, epigastralgia. Inj: Occasionally pain, burn & hematoma at inj site.
Storage
Store at temperatures below 25°C.
Action
Pharmacology: Vessel Due-F contains sulodexide, a glycosaminoglycan featuring a marked antithrombotic action either on arterial or venous systems.
Several clinical studies based on parenteral and oral product's administration show that the antithrombotic action of sulodexide is due to the dose-dependent inhibition of some coagulative factors among which, first of all, is the X-activated factor; interference with thrombin remains instead at levels of low significance and the consequences of a coagulative action are generally avoided. Antithrombotic action is sustained even by the inhibition of platelet aggregation and by the activation of circulatory and wall fibrinolytic system.
Sulodexide is also capable of normalizing altered viscosimetry parameters generally present in patients with vascular pathologies with thrombotic risk. This action mainly relies on reduced fibrinogen values.
Sulodexide pharmacological profile described so far is completed with the normalization of altered lipidic values by the action of lipoprotein lipase.
Several clinical studies based on parenteral and oral product's administration show that the antithrombotic action of sulodexide is due to the dose-dependent inhibition of some coagulative factors among which, first of all, is the X-activated factor; interference with thrombin remains instead at levels of low significance and the consequences of a coagulative action are generally avoided. Antithrombotic action is sustained even by the inhibition of platelet aggregation and by the activation of circulatory and wall fibrinolytic system.
Sulodexide is also capable of normalizing altered viscosimetry parameters generally present in patients with vascular pathologies with thrombotic risk. This action mainly relies on reduced fibrinogen values.
Sulodexide pharmacological profile described so far is completed with the normalization of altered lipidic values by the action of lipoprotein lipase.
MedsGo Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
Features
Dosage
250 LSU
Ingredients
- Sulodexide
Packaging
SoftGel Capsule 50's
Generic Name
Sulodexide
Registration Number
DR-XY22687
Classification
Prescription Drug (RX)
Product Questions
Questions
